BDTX
Black Diamond Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.12
+0.95%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
Market Cap
$121.80M
MomentumView details →
1D Return
+0.95%
YTD Return
−13.37%
RSI (14)
52.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
Market Cap
$121.80M
RSI (14)
52.6
MomentumView details →
1D Return
+0.95%
YTD Return
−13.37%
SummaryUpdated Jun 1, 2026
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is a clinical-stage biotechnology company founded in 2014 and headquartered in Cambridge, Massachusetts. Originally incorporated as ASET Therapeutics, the company rebranded to Black Diamond Therapeutics in January 2018 and went public in January 2020. The company focuses on discovering, developing, and commercializing precision medicines for patients with genetically defined tumors, particularly targeting specific mutations in cancer-driving proteins.
Similar companies
Latest newsMore news →